Loading
Benjamin Besse is a lung cancer trialist central to the Dato-DXd and HER3-DXd lung programmes.
Benjamin Besse is Head of Clinical Research at Gustave Roussy and a thoracic oncologist. His specialisms are thoracic oncology, antibody-drug conjugates in lung cancer and oncogene-driven non-small-cell lung cancer. He is a principal investigator in the TROPION-Lung and HERTHENA-Lung programmes, which test datopotamab deruxtecan and patritumab deruxtecan in lung cancer, and in trials of targeted therapy for oncogene-driven disease. His Journal of Clinical Oncology paper on TROPION-Lung01 compared datopotamab deruxtecan with docetaxel in previously treated advanced or metastatic non-small-cell lung cancer. He is linked to the TROPION-Lung01 and HERTHENA-Lung02 trials, and his publications are listed on PubMed.
Shares Intergroupe Francophone de Cancérologie Thoracique, Gustave Roussy, Non-small-cell lung cancer.
Shares Patritumab deruxtecan, Datopotamab deruxtecan, Non-small-cell lung cancer.
Shares MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer, Datopotamab deruxtecan, Non-small-cell lung cancer.
Shares Intergroupe Francophone de Cancérologie Thoracique, Non-small-cell lung cancer.
Shares TROPION-Lung01, Datopotamab deruxtecan, Non-small-cell lung cancer.
Shares Intergroupe Francophone de Cancérologie Thoracique, Non-small-cell lung cancer.